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OBJECTIVE: To identify the main severe potential drug-drug interactions in older adults with dementia and to
examine the factors associated with these interactions.
METHOD: This was a cross-sectional study. The enrolled patients were selected from six geriatrics clinics of
tertiary care hospitals across Mexico City. The patients had received a clinical diagnosis of dementia based on
the current standards and were further divided into the following two groups: those with severe drug-drug
interactions (contraindicated/severe) (n=64) and those with non-severe drug-drug interactions (moderate/
minor/absent) (n=117). Additional socio-demographic, clinical and caregiver data were included.
Potential drug-drug interactions were identified using Micromedex Drug Reax 2.0® database.
RESULTS: A total of 181 patients were enrolled, including 57 men (31.5%) and 124 women (68.5%) with a mean
age of 80.11±8.28 years. One hundred and seven (59.1%) patients in our population had potential drug-drug
interactions, of which 64 (59.81%) were severe/contraindicated. The main severe potential drug-drug interactions
were caused by the combinations citalopram/anti-platelet (11.6%), clopidogrel/omeprazole (6.1%), and clopidogrel/
aspirin (5.5%). Depression, the use of a higher number of medications, dementia severity and caregiver burden were
the most significant factors associated with severe potential drug-drug interactions.
CONCLUSIONS: Older people with dementia experience many severe potential drug-drug interactions. Anti-
depressants, antiplatelets, anti-psychotics and omeprazole were the drugs most commonly involved in
these interactions. Despite their frequent use, anti-dementia drugs were not involved in severe potential
drug-drug interactions. The number and type of medications taken, dementia severity and depression in
patients in addition to caregiver burden should be considered to avoid possible drug interactions in this
population.
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’ INTRODUCTION
Anatomical and physiological changes and impairments in
multiple organs and systems associated with aging can affect
the pharmacokinetics and pharmacodynamics of drugs (1).
Elderly patients with dementia are a group of great interest
in the study of potential drug-drug interactions (DDIs). In
addition to decreased hepatic metabolism in older adults,
the presence of cognitive deficits or neuropsychiatric symp-
toms (e.g., mood, behavioral and perception disorders) may
prompt the prescription of a wide variety of drugs, including
anti-psychotics, antidepressants, anxiolytics, mood stabilizers
and anti-dementia drugs (2-4). Most of these drugs are
extensively metabolized in the liver by cytochrome p450
isoenzymes (CYP1A2, CYP2C19, CYP2D6, CYP3A4, CYP2D6,
CYP3A4, CYP1A2, CYP2D6, CYP3A4, CYP3A4, and others)
(5,6).
A high associated comorbidity has been previously
reported for these patients, of whom 61% have three or
more diseases. Of them, musculoskeletal, cardiovascular,
metabolic/endocrine and gastrointestinal disorders are the
most common (7-9). Many of the medications prescribed
to treat these disorders are metabolized in the liver byDOI: 10.6061/clinics/2016(01)04
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cytochrome p450 isoenzymes similar to the aforementioned
psychotropics, including antiplatelet drugs (clopidogrel and
aspirin), non-steroidal anti-inflammatory drugs, omeprazole,
antidiabetic agents (metformin) and others, resulting in an
increase in poor quality prescription, potential DDIs and
adverse reactions.
Over time, new drugs (psychotropic and anti-dementia
drugs) will emerge for the treatment of dementia patients,
giving rise to new interactions and challenges for clinicians.
The factors associated with potential DDIs in elderly
patients without dementia have been previously reported
and include age, female gender, polypharmacy and high
comorbidity (10-13). Limited research has been performed to
date on potential DDIs in patients with dementia as well as
the associated factors. Moreover, the findings of previous
studies have been controversial; some studies have reported
a low frequency of potential DDIs in patients with dementia
compared to those without dementia (2,3,14), and others
have examined specific drug types, focusing primarily on
medications with anticholinergic properties (15).
To our knowledge, there are limited data available on the
factors contributing to severe potential DDIs caused by drugs
prescribed to dementia patients. Thus, it is important to identify
the main severe potential DDIs and the factors associated with
these interactions in older adults with dementia.
’ METHODS
We used the database from the ‘‘Validation of the Quality of
Life in Alzheimer’s Disease (QOL-AD) scale in Mexican patients
with dementia’’ (16), a cross sectional study the quality of life of
dementia patients. The study involved both primary caregivers
and outpatients with dementia from different health institutions
located in Mexico City. The patients were interviewed at
scheduled appointments at six general hospitals. The study took
place from January 2007 to January 2010 and included patients
aged 60 years or older with dementia. The enrolled patients
were required to be able to read and write. The caregiver was
included if he/she was able to read and write, was not paid and
generally knew more than the patient about the his or her
environment and care. The main exclusion criteria were as
follows: (i) the presence of acute and/or exacerbated chronic
disease within the 30 days before the interview that could have
affected the quality of the responses to the questionnaires, as
determined by the study’s medical staff; (ii) decreased alertness
(for any reason); (iii) severe aphasia; (iv) visual and hearing
impairments, resulting in difficulty for the patient/caregiver
with filling out the questionnaires; (v) the presence of other
neurological diseases that could have influenced the diagnosis
of dementia; and (vi) institutionalization of the patient.
Patient variables
We included data from 181 outpatients who were 60 years of
age or older and had a clinical diagnosis of dementia. Dementia
(e.g., Alzheimer’s, vascular, mixed, frontotemporal and Lewy
body dementia) had been previously diagnosed by a group of
geriatricians dedicated to the study of dementia according to
international criteria; these criteria have been described in a
previous publication (17).
Measurements
Interaction analysis. Potential DDIs were identified
using Micromedex Drug Reax 2.0s database. We focused
our study on the worst potential DDIs because they tend to
have a greater clinical impact on patients’ well-being. For this
analysis, potential DDIs were classified into the following
2 general categories: contraindicated/severe potential DDIs
were combined in a ‘‘severe interactions’’ category to represent
the worst possible outcomes of a given drug combination
and moderate/minor/absent potential DDIs were combined
to form a ‘‘non-severe interaction’’ group. The groups were
labeled and compared as ‘‘severe’’ versus ‘‘non-severe’’.
Number of medications
A list of medications taken by the elderly subjects was
generated based on a review of the clinical records and it was
confirmed by the physicians. The quantitative variable in this
study was the total number of medications taken.
Comorbidity
We used a Spanish version of the Charlson index. This
scale includes a list of 19 diseases and their complications.
Comorbidities were determined by caregiver interviews and
a review of the clinic’s records and the total score was used
for this variable (18).
Caregiver burden was determined by the Screen for
Caregiver Burden (25-item scale). It has been adapted and
validated for use in the Mexican population. We analyzed the
total score achieved on this test (ranging from 0 to 100) (19).
Another measure employed was a Spanish version of the
Dysexecutive Questionnaire (DEX), a 20-item questionnaire that
uses a Likert scale ranging from 0 to 4 points. For this measure,
we assessed the total score (ranging from 0 to 80), with the
primary caregiver as the interviewed party (proxy) (20).
The Mini-Mental State Examination (MMSE) was used as
an indirect indicator of dementia severity. We used a version
that has been previously validated for use in the Mexican
population (21).
The Barthel index was applied to assess the Spanish
version of the Basic Activities of Daily Living (ADL) scale.
We analyzed the total score (ranging from 0 to 100) (22).
The Lawton Scale was used to evaluate instrumental
activities of daily living (IADL). This scale contains eight
items, and we analyzed the cumulative score (ranging from
0 to 8) (23).
To evaluate the presence of depression, we used the
depression subscale of the Neuropsychiatric Inventory
(NPI-D). The frequency score was classified as presence=1 or
absence=0 for a 12-item inventory validated for use in the
Mexican population that, was completed by the caregivers (24).
The original project was approved by the National Scientific
Research Committee of IMSS (Approval Number 2006-785-065).
All patients and caregivers provided written informed consent.
Descriptive analyses were performed using frequencies,
percentages and Pearson’s Chi2 test (comparative analysis)
for qualitative variables. The mean± SD and Student’s t-test
(comparative analysis) were used to analyze quantitative
variables. The variables associated with potential DDIs
(po0.05) were included in a multivariate model using
multiple logistic regression. We used STATAs version 11
software (StataCorp, 2009) to perform analysis.
’ RESULTS
We evaluated 181 outpatients from the original study,
including 57 males (31.5%) and 124 females (68.5%) with a
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mean age of 80.11±8.28 years. The patient characteristics are
displayed in Table 1. The prevalence of potential DDIs in our
population was 59.1%, with 59.8% being classified as severe.
Anti-dementia drugs were the most widely used medications
(58.6%), followed by anti-depressants (44.2%), anti-psycho-
tics (25.4%) and, to a much lesser degree, sedatives (12.2%).
However, none of the anti-dementia drugs were classified as
‘‘severe DDIs’’ (Tables 1 and 2).
The top ten potential DDIs are included in Table 2. The
most prevalent interaction in our population occurred with
the combined use of citalopram and antiplatelet drugs (n=21;
11.6%) (Table 2).
The independent variables were compared according to
the severity of the potential DDIs (severe or non-severe).
Comorbidity, depression, polypharmacy, dementia severity
and caregiver burden were the most significant factors and
were thus used in comparative analysis (Table 3).
The significant variables were included in the final
regression model. This model revealed that the variables
associated with severe potential DDIs were depression, the
number of drugs taken, dementia severity and caregiver
burden. Depression was by far the most significant, followed
by the number of drugs taken. In addition, caregiver burden
and dementia severity exhibited positive but diminished
associations with the severe potential DDIs (Table 4).
’ DISCUSSION
This study provides insights into the frequency of severe
potential DDIs in older people with dementia (35.3%). The
frequency observed in this study is higher than that of a
previous report (26.6%) (25). We speculate that this difference
between studies could be due to the higher frequency of
neuropsychiatric symptoms in this study (depression was
the only factor associated with severe interactions). Other
studies have found a similar high frequency of the use of
antidepressants, anxiolytics and antipsychotics in patients
with dementia (2,15,25,26).
One of the main objectives of this study was to identify the
main severe DDIs because they are the most likely to have
poor outcomes in the clinical setting; however, the results of
studies based on Micromedex reports should be considered
with caution. For example, the main potential DDI (Table 2)
determined in this study (citalopram/antiplatelet) according
to Micromedex database has been shown to have null or
discrete associations with the risk of gastrointestinal bleeding
in several clinical contexts in previous clinical studies.
Therefore, further studies should be performed to determine
the real risk of bleeding (27,28).
Table 1 - General patient characteristics.
Factors N=181 (%)
Age 80.11±8.28
Sex
Male 57 (31.50)
Female 124 (68.50)
Schooling (years) 7.62±5.34
Total comorbidity score (Charlson index) 2.56±1.57
Number of drugs 5.20±3.04
Executive function (DEX) total score 17.54±18.38
Dementia severity (MMSE) total score 16.80±6.70
ADL (Barthel) 73.92±29.51
IADL (Lawton) 5.0±5.33
Caregiver burden (SCB) 21.91±15.97
NPI Depression item (yes) 111 (61.33)
Drug-drug interactions
Yes 107 (59.10)
No 74 (40.90)
Severity of Interactions
Mild 3 (2.80)
Moderate 40 (37.38)
Severe/contraindicated 64 (59.81)
Mini-Mental State Examination (MMSE); Dysexecutive Questionnaire
(DEX); Barthel Activities of Daily Living scale (ADL); Lawton Instrumental
Activities Daily Living scale (IADL); 12-item Neuropsychiatric Inventory
(NPI-D); Screen for Caregiver Burden (SCB).
Table 2 - Top ten severe potential DDIs (severe and contraindicated).
Type Effect n Interaction (%) Patient (%)
Citalopram/ Anti-platelet Concurrent use may result in an increased risk of bleeding. (Documentation:
Good)
21 6.7 11.6
Clopidogrel/ Omeprazole Concurrent use may result in reduction in clinical efficacy of clopidogrel and
increased risk of thrombosis. (Documentation: Excellent)
11 3.5 6.1
Clopidogrel/ Aspirin Concurrent use may result in an increased risk of bleeding. (Documentation: Fair) 10 3.2 5.5
Citalopram/ Omeprazole Concurrent use may result in increased citalopram exposure and risk of QT interval
prolongation. (Documentation: Fair)
8 2.5 4.4
Escitalopram/ Anti-platelet Concurrent use may result in an increased risk of bleeding. (Documentation:
Good)
5 1.6 2.7
Citalopram/ Quetiapine Concurrent use may result in increased risk of QT interval prolongation.
(Evidence level: Fair)
5 1.6 2.7
Paroxetine/ Anti-platelet Concurrent use may result in an increased risk of bleeding. (Documentation:
Good)
4 1.3 2.2
Amlodipine/ Clopidogrel Concurrent use may result in decreased antiplatelet effects and increased risk
of thrombotic events. (Documentation: Excellent)
3 0.3 1.6
Citalopram/ Risperidone Concurrent use may result in increased risks of QT interval prolongation and
torsade de pointes. (Documentation: Good)
3 0.3 1.6
Citalopram/ Haloperidol Concurrent use may result in an increased risk of QT interval prolongation.
(Documentation: Good)
3 0.3 1.6
Documentation: Excellent (controlled studies have clearly established the existence of the interaction), Good (documentation strongly suggests that the
interaction exists, but well-controlled studies are lacking), Fair (available documentation is poor, but pharmacologic considerations have led clinicians to
suspect that the interaction exists; or the documentation is good for a pharmacologically similar drug), and Unknown (Unknown). The documentation is
based on information obtained from Micromedex®.
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Conflicting results have been reported regarding the increa-
sed risk of the second most frequent potential DDI observed in
this study (clopidogrel/omeprazole). Studies based on Micro-
medex reports have indicated that their concurrent use may
result in an increased risk of bleeding. However, a recent
clinical study found that in healthy volunteers omeprazole,
esomeprazole and lansoprazole caused a relative decrease in
exposure to the active metabolite of clopidogrel by of up to
50%, leading to modest decreases in its antiplatelet effect (29).
Also in contrast to data from Micromedex, epidemiological
studies have provided no evidence that this drug combination
increases the risk of gastrointestinal bleeding, including patients
who are receiving aspirin and clopidogrel. Even in patients
receiving aspirin and clopidogrel, prophylactic use of a Proton
Pump Inhibitors (PPI) has been shown to reduce the rate of
upper gastrointestinal bleeding (30). Similar findings have been
reported regarding a potential DDI between clopidogrel and
paroxetine; while numerous studies have indicated a high risk
of bleeding, this result has essentially been based on the
evaluation of registries and retrospective or case–control studies
(31). A recent basic sciences study of healthy volunteers has
found that paroxetine inhibits formation of the active metabo-
lite of clopidogrel, thereby modifying the pharmacodynamics
of this product in terms of its antiplatelet effects and conse-
quently, its efficacy (32).
Regarding the factors associated with severe potential
DDIs, the final regression model and comparative analysis
revealed that the number of medications taken is a risk factor
for the presence of severe potential DDIs, in agreement with
other studies analyzing these interactions in older adults
with and without dementia (2,10,11,9,33).
A secondary objective of this study was to identify different
factors associated with the presence of potential DDIs; in this
regard, depression was the main neuropsychiatric symptom
associated with severe potential DDIs. One of the most widely
used treatments for depression is the selective serotonin
reuptake inhibitors (SSRIs). SSRIs are currently recommended
as the first-line treatment for depression in older adults
according to several clinical guidelines (34,35). This group of
antidepressant should be used with caution in these patients.
Clinical studies should be performed to confirm these
findings.
A modest association was found between caregiver burden
and severe potential DDIs (Tables 3 and 4). Previous reports
have shown that caregivers tend to have greater physical and
psychological burdens than the general population, and these
burdens have been demonstrated to result in hospitalization
of the patients who they care for (36). Caregivers may play
an important role in drug administration, and when they are
well trained, their help is very important (36). However, in a
situation in which dementia represents a heavy burden, a
caregiver’s persistence could cause physicians to prescribe
more or specific medications to control a patient’s neuropsy-
chiatric symptoms, leading to severe potential DDIs and
resulting in supplementary non-pharmacological treatment.
A greater number of diseases affected the patients with a
lower MMSE score than those with a higher MMSE score;
therefore, the increased numbers of prescription drugs taken by
the patients in this study may be explained by the successive
selection of patients attending memory clinics and may not
be directly related to their cognitive statuses. Therefore,
longitudinal studies should be conducted to confirm this
relationship.
There were several limitations of this study. It is important
to note that the hospitals at which the outpatients were
recruited are specialized institutions, and this study did
not include institutionalized or community-dwelling older
adults. Thus, our results can only be applied to institutions
Table 3 - Comparative analysis of the relationships between potential severe (contraindicated/severe) and non-severe (moderate/mild/
none) interactions and other factors.
Factors Severe interactions Mean ± SD Non-severe interactions Mean ± SD p-value
Age (years) 80.89±7.6 79.6±8.5 0.35
Sex
Female n (%) 83 (70.94) 41 (64.0) 0.34
Schooling 8.7±5.5 7.0±5.1 0.05
Comorbidity (Charlson index) 3.0±1.7 2.2±1.4 0.002
Number of drugs 7.68±2.6 3.8±2.2 o0.001
Executive function (DEX) 28.1±28.6 27.2±18.8 0.75
Dementia severity (MMSE) 18.6±5.9 15.7±6.8 0.005
Activities of daily living (Barthel index) 70.9±30.1 75.5±29.1 0.31
Instrumental activities (Lawton) 4.2±4.8 5.43±5.5 0.14
Caregiver burden (SCB 25-item) 25.3±18.6 20.0±14.0 0.03
Depression (NPI) (yes) n (%) 48 (75.0) 63 (53.85) 0.005
Pearson’s Chi2 test was used for qualitative variables.
Student’s t-test was used for quantitative variables.
Mini-Mental State Examination (MMSE), Screen for Caregiver Burden (SCB), Neuropsychiatric Inventory (NPI).
Table 4 - Factors associated with the presence of severe (contraindicated/severe) potential drug-drug interactions.
Variables OR CI (95%) p-value
Dementia severity (MMSE) total score 1.08 1.01-1.16 0.01
Comorbidity (Charlson index) total score 0.89 0.64-1.20 0.47
Number of medications 1.88 1.53-2.32 o0.001
Caregiver burden (SCB) total score 1.03 1.00-1.06 0.01
Depression (NPI) (yes) 3.19 1.24-8.20 0.01
Log likelihood=-70.819097, Pseudo R2=0.3977, Prob.4chi2=0.0000.
Mini-Mental State Examination (MMSE), Screen for Caregiver Burden (SCB), Neuropsychiatric Inventory (NPI).
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with similar characteristics. In addition, this was a cross-
sectional study, and further research examining the long-
itudinal association between caregiver burden and other
factors and severe potential DDIs is necessary.
Another limitation was the lack of data on the outcomes of
the potential DDIs identified, which is attributed to the
nature of the study. The scores of the MMSE, which was used
as a measure of the severity of dementia, should be considered
with caution due to the limitations associated with its use in
older adults with a low education level.
Despite these limitations, we believe that this study contri-
butes to current knowledge of the frequency of potential
DDIs and the relationships between severe potential DDIs and
the contrubuting factors in dementia patients.
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